Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2019 Jan 15

PMID 30637221

Citations 6

Authors

Yan Li

Lun-Gen Lu

Affiliations

Soon will be listed here.

Abstract

Bile acids (BAs) are the major metabolic product of cholesterol, having detergent-like activities and being responsible for absorption of lipid and lipid-soluble vitamins. In addition, it has been increasingly recognized that BAs are important signaling molecules, regulating energy metabolism and immunity. Under physiological circumstances, synthesis and transport of BAs are precisely regulated to maintain bile acid homeostasis. Disruption of bile acid homeostasis results in pathological cholestasis and metabolic liver diseases. During the last decades, BAs have been gradually recognized as an important therapeutic target for novel treatment in chronic liver diseases. This review will provide an update on the current understanding of synthesis, transport and regulation of BAs, with a focus on the therapeutic roles of bile acid signaling in chronic liver diseases.

Citing Articles

Bile Acids and Liver Cancer: Molecular Mechanism and Therapeutic Prospects.

Zhang X, Shi L, Lu X, Zheng W, Shi J, Yu S Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338306 PMC: 11435149. DOI: 10.3390/ph17091142.

Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases.

Wang Y, Xu H, Zhou X, Chen W, Zhou H Med Rev (2021). 2024; 4(4):262-283.

PMID: 39135605 PMC: 11317083. DOI: 10.1515/mr-2024-0020.

Conjugated Bile Acids Promote Lymphangiogenesis by Modulation of the Reactive Oxygen Species-p90RSK-Vascular Endothelial Growth Factor Receptor 3 Pathway.

Banerjee P, Kumaravel S, Roy S, Gaddam N, Odeh J, Bayless K Cells. 2023; 12(4).

PMID: 36831193 PMC: 9953922. DOI: 10.3390/cells12040526.

A Current Understanding of Bile Acids in Chronic Liver Disease.

Farooqui N, Elhence A, Shalimar J Clin Exp Hepatol. 2022; 12(1):155-173.

PMID: 35068796 PMC: 8766695. DOI: 10.1016/j.jceh.2021.08.017.

Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid....

Karhus M, Bronden A, Forman J, Haaber A, Vilsboll T, Sonne D BMJ Open. 2021; 11(2):e044711.

PMID: 33558360 PMC: 7871677. DOI: 10.1136/bmjopen-2020-044711.

References

BAKER D, Wang S, Bell D, Drevon C, Davis R . One or more labile proteins regulate the stability of chimeric mRNAs containing the 3'-untranslated region of cholesterol-7alpha -hydroxylase mRNA. J Biol Chem. 2000; 275(26):19985-91. DOI: 10.1074/jbc.M002351200. View

Holt J, Luo G, Billin A, Bisi J, McNeill Y, Kozarsky K . Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003; 17(13):1581-91. PMC: 196131. DOI: 10.1101/gad.1083503. View

Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K . Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004; 10(6):894-8. PMC: 4727018. DOI: 10.3748/wjg.v10.i6.894. View

Galman C, Angelin B, Rudling M . Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology. 2005; 129(5):1445-53. DOI: 10.1053/j.gastro.2005.09.009. View

Ridlon J, Kang D, Hylemon P . Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2005; 47(2):241-59. DOI: 10.1194/jlr.R500013-JLR200. View

Song K, Chiang J . Glucagon and cAMP inhibit cholesterol 7alpha-hydroxylase (CYP7A1) gene expression in human hepatocytes: discordant regulation of bile acid synthesis and gluconeogenesis. Hepatology. 2005; 43(1):117-25. DOI: 10.1002/hep.20919. View

Li T, Jahan A, Chiang J . Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology. 2006; 43(6):1202-10. PMC: 1526464. DOI: 10.1002/hep.21183. View

Li T, Kong X, Owsley E, Ellis E, Strom S, Chiang J . Insulin regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes: roles of forkhead box O1 and sterol regulatory element-binding protein 1c. J Biol Chem. 2006; 281(39):28745-54. PMC: 1576296. DOI: 10.1074/jbc.M605815200. View

Sanyal S, Bavner A, Haroniti A, Nilsson L, Lundasen T, Rehnmark S . Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc Natl Acad Sci U S A. 2007; 104(40):15665-70. PMC: 2000397. DOI: 10.1073/pnas.0706736104. View

10.

Iwasaki S, Akisawa N, Saibara T, Onishi S . Fibrate for treatment of primary biliary cirrhosis. Hepatol Res. 2007; 37 Suppl 3:S515-7. DOI: 10.1111/j.1872-034X.2007.00232.x. View

11.

Zollner G, Trauner M . Mechanisms of cholestasis. Clin Liver Dis. 2008; 12(1):1-26, vii. DOI: 10.1016/j.cld.2007.11.010. View

12.

Song K, Li T, Owsley E, Strom S, Chiang J . Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology. 2008; 49(1):297-305. PMC: 2614454. DOI: 10.1002/hep.22627. View

13.

Chiang J . Bile acids: regulation of synthesis. J Lipid Res. 2009; 50(10):1955-66. PMC: 2739756. DOI: 10.1194/jlr.R900010-JLR200. View

14.

Perez M, Briz O . Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009; 15(14):1677-89. PMC: 2668773. DOI: 10.3748/wjg.15.1677. View

15.

Chapman R, Fevery J, Kalloo A, Nagorney D, Boberg K, Shneider B . Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51(2):660-78. DOI: 10.1002/hep.23294. View

16.

Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G . Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol. 2010; 78(4):617-30. PMC: 2981390. DOI: 10.1124/mol.110.064501. View

17.

Hohenester S, Maillette de Buy Wenniger L, Paulusma C, van Vliet S, Jefferson D, Elferink R . A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 2011; 55(1):173-83. DOI: 10.1002/hep.24691. View

18.

Adorini L, Pruzanski M, Shapiro D . Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012; 17(17-18):988-97. DOI: 10.1016/j.drudis.2012.05.012. View

19.

Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T . Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2012; 57(5):1931-41. DOI: 10.1002/hep.26018. View

20.

Rudic J, Poropat G, Krstic M, Bjelakovic G, Gluud C . Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012; 12:CD000551. PMC: 7045744. DOI: 10.1002/14651858.CD000551.pub3. View